-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

Benzinga·04/27/2026 11:57:53
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.